Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11825819

Crnn loss of function rodent model

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11820982

Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11820826

Anti-NPR1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11820815

Human antibodies to human delta like ligand 4

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11814428

Anti-PTCRA antibody-drug conjugates and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11806398

Citrate buffered VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786603

Optimized transglutaminase site-specific antibody conjugation

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11787867

Anti-GITR antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786606

Site-specific quantitation of drug conjugations

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11779633

Glucagon-like peptide 1 receptor agonists and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11780907

Human antibodies to influenza hemagglutinin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11778995

Genetically modified non-human animals and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11773156

Anti-hemagglutinin antibodies and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11771743

Methods for preventing or treating allergy by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11773393

Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibito

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11771762

Anti-ErbB3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11769597

Methods of associating genetic variants with a clinical outcome in patients suffering from

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11767526

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11767358

Human antibodies to Bet v 1 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11766032

Genetically modified non-human animals expressing human EPO

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11760775

Steroids and protein-conjugates thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11759476

Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Be

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11752214

Protein-antiviral compound conjugates

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11753459

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted